Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Koate-dvi Generic Name & Formulations
Legal Class
Rx
General Description
Antihemophilic Factor VIII (human) 250 IU, 500 IU, 1000 IU; per bottle; dried concentrate for IV infusion after reconstitution; contains albumin.
Pharmacological Class
Clotting factor.
How Supplied
Single-dose bottle—1 (w. diluent)
Manufacturer
Koate-dvi Indications
Indications
Prevention and control of hemorrhagic episodes or in order to perform emergency or elective surgery in Hemophilia A patients.
Koate-dvi Dosage and Administration
Adult
Dosage Required (IU) = Body Weight (kg) × Desired % Factor VIII Increase × 0.5. Individualize. Infuse over 5–10 minutes if tolerated. Use filter needle. Hemorrhage: Mild: 10 IU/kg as single dose. Moderate: 15–25 IU/kg, then 10–15 IU/kg every 8–12hrs if needed. Severe: initially 40–50 IU/kg, then 20–25 IU/kg every 8–12hrs. Major surgery: pre-op dose: 50 IU/kg, then verify Factor VIII level achieved prior to surgery; may repeat every 6–12hrs initially and for 10–14 days until healing complete.
Children
Not recommended.
Koate-dvi Contraindications
Not Applicable
Koate-dvi Boxed Warnings
Not Applicable
Koate-dvi Warnings/Precautions
Warnings/Precautions
Not for von Willebrand's disease. Confirm Factor VIII deficiency prior to treatment. Contains human plasma; monitor for possible infection transmission. Large or frequent doses: monitor hematocrit for signs of progressive anemia. Monitor for development of Factor VIII inhibitors. Pregnancy (Cat.C).
Koate-dvi Pharmacokinetics
See Literature
Koate-dvi Interactions
Not Applicable
Koate-dvi Adverse Reactions
Adverse Reactions
Allergic reactions, tingling sensations, blurred vision, headache, GI upset, jittery feeling, antibody formation.
Koate-dvi Clinical Trials
See Literature
Koate-dvi Note
Not Applicable
Koate-dvi Patient Counseling
See Literature
